AlzGene

AlzGene - Gene overview of all published AD-association studies for BCHE

Gene:

BCHE (CHE1; E1)

View on PDGene

Protein:

butyrylcholinesterase

Chromosome:

3 (View: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 X Y MT)

Status:

Updated 29 January 2010

1. Case-Control Studies (by ethnic group)
				AD Cases				Normal Controls
Study	Population	Source	# Polys	# Subjects (% women)	DX	Onset Age (range)	Age (range)	# Subjects (% women)	Age (range)	Result	Comment
Caucasian
Alvarez-Arcaya, 2000	Spain	CL	1 (detail)	249 (68%)	C	71.5 + 9.1 (40-95)	75.3 + 9.3 (50-98)	250 (75%)	79.9 + 7.9 (63-98)	Positive
Beyer, 2005	Spain	CL	1 (detail)	206 (62%)	C	-	72.6 (48-85)	181 (60%)	69.6 (45-84)	Positive
Bizzarro, 2010	Italy	CL	1 (detail)	167 (62%)	C	-	73.3 + 8.1 (-)	129 (52%)	75.3 + 7.7 (-)	Positive
Blomqvist, 2005	Overlaps with Emahazion, 2001	CL	1 (detail)	-	-	-	-	-	-	n.a.
Blomqvist, 2005	Overlaps with Prince, 2001	CL	1 (detail)	-	-	-	-	-	-	n.a.
Combarros, 2005	Overlaps with Alvarez-Arcaya, 2000	CL	1 (detail)	-	C	-	-	-	-	n.a.
Combarros, 2007	Overlaps with Alvarez-Arcaya, 2000	CL	1 (detail)	183 (71%)	C	71.6 + 8.9 (48-93)	74.2 + 8.9 (50-97)	169 (74%)	79.7 + 7.6 (66-98)	n.a.
Cook, 2005	UK	CL	3 (detail)	215 (-)	N	-	-	320 (-)	-	Negative
Corder, 2006	Overlaps with Lehmann, 1997	CL	1 (detail)	315 (-)	M	-	-	260 (-)	-	n.a.
Corder, 2008	Overlaps with Blomqvist, 2005	CL	1 (detail)	938 (-)	U	-	-	397 (-)	-	n.a.
Deniz-Naranjo, 2007	Spain	CL	1 (detail)	282 (69%)	C	-	-	-	312 + 120 (-)	Positive
Emahazion, 2001	Scotland	CL	1 (detail)	121 (-)	C	-	-	152 (-)	-	Negative
Giedraitis, 2009	Sweden (ULSAM)	CL	1 (detail)	86 (0%)	C	80.2 (72-85)	-	404 (0%)	81.8 (80-84)	Negative
Grubber, 1999	USA	CL	1 (detail)	245 (58%)	C	67.9 + 8.3 (40-85)	72.7 + 8 (42-93)	241 (52%)	69.7 + 7.3 (37-86)	Negative
Helbecque, 1998	Europe (mixed)	CL	1 (detail)	336 (60%)	C	66.5 + 8.1 (-)	69.8 + 7.9 (-)	344 (49%)	72.2 + 13.8 (-)	Negative
Hiltunen, 1998	Finland	CL	1 (detail)	78 (74%)	M	73 + 5 (-)	-	97 (66%)	72 + 4 (-)	Negative
Kehoe, 1998	UK	CL	1 (detail)	181 (60%)	M	70 + 9 (-)	-	71 (52%)	73.4 + 6.2 (-)	Negative
Laws, 1999	Australia	CL,CO	1 (detail)	237 (-)	C	-	-	347 (-)	-	Negative
Lehmann, 1997	UK	CL	1 (detail)	149 (58%)	M	-	76.5 (-)	104 (75%)	-	Positive
Mateo, 2008	Overlaps with Alvarez-Arcaya, 2000	CL	1 (detail)	231 (68%)	C	71.3 + 8.8 (48-93)	75.6 + 9 (50-97)	221 (60%)	80.1 + 8 (63-98)	n.a.
Mattila, 2000	Finland	CL	1 (detail)	80 (64%)	M	-	-	67 (45%)	75.9 + 7.3 (-)	Positive
McIlroy, 2000	Ireland	CL	1 (detail)	175 (65%)	C	-	77.7 + 5.9 (67-94)	187 (69%)	77.1 + 6 (67-96)	Positive
Panegyres, 1999	Australia	CL	1 (detail)	38 (-)	N	-	-	30 (-)	-	Positive
Piccardi, 2007	Italy	CL	1 (detail)	158 (73%)	C	74.4 + 6.7 (-)	76.8 + 6.9 (-)	118 (64%)	65.7 + 7.8 (-)	Negative
Prince, 2001	Sweden	CL	1 (detail)	204 (61%)	M	-	-	186 (58%)	-	Negative
Russ, 1998	UK	CO	1 (detail)	203 (-)	C	-	82.4 + 6.7 (-)	122 (-)	80.4 + 4.6 (-)	Negative
Scacchi , 2008	Italy	CL	2 (detail)	471 (69%)	C	-	78.5 + 5.2 (60-96)	254 (60%)	77.5 + 8.1 (60-95)	Negative
Singleton, 1998	UK	CL	1 (detail)	119 (-)	N	-	78.3 + 9.4 (-)	83 (-)	78.3 + 7.7 (-)	Negative
Tilley, 1999	UK	CL	1 (detail)	177 (62%)	N	-	81.6 + 8.6 (55-101)	118 (31%)	72.8 + 8.7 (58-94)	Positive
Wiebusch, 1999	Canada	CL	2 (detail)	135 (53%)	N	-	78 + 7.8 (-)	70 (36%)	74 + 9.2 (-)	Positive
Asian
Bi, 2001	China		1 (detail)	38 (-)	U	-	-	40 (-)	-	Negative
Ki, 1999	Korea	CL	1 (detail)	78 (78%)	C	-	73.2 (-)	74 (-)	73.8 (-)	Negative
Kim, 2001b	Korea		1 (detail)	164 (-)	C	-	71.7 + 8.7 (-)	239 (-)	69 + 5 (-)	Negative
Lee, 2000	China	CL	1 (detail)	89 (53%)	C	69.1 + 9.9 (-)	-	101 (45%)	73 + 4.6 (-)	Negative
Yamada, 1998	Japan	CL	1 (detail)	48 (-)	N	-	84.6 + 7.3 (-)	107 (-)	85.3 + 7.9 (-)	Negative
Yamada, 2002	Japan	CL	1 (detail)	82 (-)	N	-	86.1 + 7.9 (62-104)	119 (-)	85.7 + 8 (65-103)	Negative
Yamamoto, 1999	Japan	CL	1 (detail)	203 (-)	C	-	68.2 + 8.5 (-)	288 (-)	68.5 + 7.4 (-)	Negative
Other/Mixed
Brindle, 1998	USA, Canada	CL	1 (detail)	188 (64%)	M	-	73.2 (-)	165 (44%)	63.4 (-)	Negative
Crawford, 1998	USA	CL,CO	1 (detail)	391 (31%)	C	73 + 6.2 (-)	-	201 (60%)	72.3 + 7.1 (-)	Negative
Raygani, 2004	Iran	CL	1 (detail)	105 (57%)	C	-	75 + 10 (-)	129 (65%)	73.5 + 11.5 (-)	Positive

Contact us if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.

2. Family-Based Studies (by ethnic group)
				Affecteds				Unaffecteds
Study	Population	# Polys	# Families	# Subjects (% women)	DX	Onset Age (range)	Age (range)	# Subjects (% women)	Age (range)	Result	Comment
Caucasian
Grubber, 1999	USA	1 (detail)	163	163 (-)	C	-	-	163 (-)	-	Negative
Other/Mixed
Bertram, 2000	USA	1 (detail)	220	460 (-)	M	-	-	367 (-)	-	Negative

Contact us if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.

Source:  Source of case population -> “CL” (clinic-based), “PO” (population-based), or “CO” (community-based).
# Polys:  Number of polymorphisms tested per gene and per sample.
Onset Age and Age:  Mean or median age at onset or examination, respectively.
DX:  Criteria used to determine AD diagnosis -> "C" (clinical AD diagnosis), "N" (neuropathological AD diagnosis), "M" (mixed, i.e. AD sample contains both clinical and neuropathological cases), "U" (unknown).
Result:  Overall conclusion reached by authors of the original publication (“positive” usually indicates significant (P<0.05) association in at least one of the performed analyses, and “negative” indicates no evidence for significant association, while “trend” indicates results in between); results obtained in duplicate or largely overlapping samples are listed as "n.a.".
(-) :  Either no data provided or in case of overlap, data included in original study.

AlzGene Recent Updates

AlzGene Top Results